嘉实上证科创板生物医药ETF发起联接A(021060)申购赎回 |
|
|
| 报告期 |
期初总份额(份) |
期末总份额(份) |
期间总申购份额(份) |
期间总赎回份额(份) |
期间净申赎份额(份) |
净申赎比例 |
| 2026/9/30 |
37,974,900 |
48,024,800 |
31,904,900 |
21,855,000 |
10,049,900 |
26.46% |
| 2026/6/30 |
23,865,600 |
37,974,900 |
27,112,500 |
13,003,200 |
14,109,300 |
59.12% |
| 2026/6/30 |
32,736,500 |
37,974,900 |
12,735,600 |
7,497,160 |
5,238,440 |
16% |
| 2026/3/31 |
23,865,600 |
32,736,500 |
14,376,900 |
5,506,030 |
8,870,870 |
37.17% |
| 2025/12/31 |
15,244,100 |
23,865,600 |
81,135,600 |
72,514,200 |
8,621,400 |
56.56% |
| 2025/12/31 |
21,381,700 |
23,865,600 |
7,449,900 |
4,966,010 |
2,483,890 |
11.62% |
| 2025/9/30 |
17,242,000 |
21,381,700 |
12,180,900 |
8,041,180 |
4,139,720 |
24.01% |
| 2025/6/30 |
15,244,100 |
17,242,000 |
61,504,800 |
59,507,000 |
1,997,800 |
13.11% |
| 2025/6/30 |
41,047,000 |
17,242,000 |
31,976,700 |
55,781,700 |
-23,805,000 |
-57.99% |
| 2025/3/31 |
15,244,100 |
41,047,000 |
29,528,100 |
3,725,320 |
25,802,780 |
169.26% |
| 2024/12/31 |
10,062,200 |
15,244,100 |
8,277,070 |
3,095,140 |
5,181,930 |
51.5% |
| 2024/12/31 |
10,322,900 |
15,244,100 |
7,902,480 |
2,981,270 |
4,921,210 |
47.67% |
| 2024/9/30 |
10,041,200 |
10,322,900 |
344,462 |
62,691 |
281,771 |
2.81% |
*注:新浪财经提醒:以上数据由合作伙伴提供,仅供参考,交易请以正式公告数据为准。